Table 3.

Comparison of correlation of risk results for spike IgG and PsV-nAb ID50 across three randomized, placebo-controlled COVID-19 vaccine efficacy trials (U.S. study sites)

Vaccine Platforma	Trial	Ab Marker at 2 or 4 Wksb Post-Vaccination	Follow-Up Post Vaccination	Estimated Hazard Ratio per 10-fold Increase in the Marker (95% CI)	P Value	Q Value	FWER-Adjusted P Value
mRNA	COVE	Spike IgG	126 days	0.66 (0.50, 0.88)	0.005	0.014	0.010
Ad26	ENSEMBLE-U.S.	Spike IgG	83 days	0.62 (0.28, 1.37)	0.24	0.35	0.36
Recombinant Protein	PREVENT-19	Spike IgG	73 days	0.36 (0.20, 0.64)	<0.001	0.005	0.005
mRNA	COVE	RBD IgG	126 days	0.57 (0.40, 0.82)	0.002	0.008	0.008
Ad26	ENSEMBLE-U.S.	RBD IgG	83 days	0.50 (0.21, 1.21)	0.13	0.24	0.22
Recombinant Protein	PREVENT-19	RBD IgG	73 days	0.35 (0.18, 0.69)	0.002	0.012	0.013
mRNA	COVE	PsV-nAb ID50	126 days	0.42 (0.27, 0.65)	<0.001	0.002	0.003
Ad26	ENSEMBLE-U.S.	PsV-nAb ID50	83 days	0.38 (0.13, 1.12)	0.078	0.22	0.20
Recombinant Protein	PREVENT-19	PsV-nAb ID50	73 days	0.39 (0.19, 0.82)	0.013	0.032	0.030

^aCOVE: Moderna mRNA-1273 spike vaccine; ENSEMBLE: Janssen Ad26 vector spike vaccine Ad26.CoV2.S; PREVENT-19: Novavax recombinant spike protein vaccine NVX-CoV2373.

^bIn COVE and ENSEMBLE, the antibody markers were measured 4 weeks post-vaccination, compared to 2 weeks post-vaccination in PREVENT-19.